Navigation Links
CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients
Date:10/7/2008

esponding to initial therapy and continued in year 2 for remitters. Based on average wholesale prices for the treatments, estimate of treatment costs showed that CIMZIA provided more cost savings during induction and maintenance phases of treatment when compared to infliximab and adalimumab.

A cohort budget analysis, with uptakes of 60 percent, 30 percent and 10 percent in year 1 and 50 percent, 30 percent and 20 percent in year 2 for infliximab, adalimumab and CIMZIA, respectively, was performed for a healthcare plan of 5 million members with a CD prevalence of 162 per 100,000 and incidence rate of 9.6 per 100,000. Results showed that access to CIMZIA provided a savings of more than $1.5 million compared to a healthcare plan that did not include CIMZIA. The data suggest that based on standard regimens for each of the TNF alpha blockers for CD, CIMZIA may be less costly than the two biologics studied.

About WELCOME

The WELCOME study is a 539 patient Phase IIIb multicenter 26-Week trial Evaluating the clinical benefit and tolerability of certoLizumab pegol induCtiOn and Maintenance in patients suffering from Crohn's disease with prior loss of response or intolErance to infliximab. It consists of an open-label induction phase (400 mg of CIMZIA sub-cutaneously at Weeks 0, 2 and 4) and a double-blind maintenance period (400 mg of CIMZIA every 2 or 4 weeks from Week 6). The primary endpoint was defined as the rate of response (defined as a decrease in CDAI score less than or equal to 100 points from baseline) at Week 6. Remission was defined as a CDAI score of greater than or equal to 150 points. After the induction period, 62 percent of patients achieved response and 39 percent achieved remission. One-third of patients had responded to treatment by Week 2 (33 percent) and more than forty percent (44 percent) had responded by Week 4.

About the PRECiSE Clinical Trial Program

PRECiSE, one of the largest, most comprehensive development pro
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
3. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
4. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
5. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
6. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
7. Raptor Pharmaceuticals Provides Update of Product Programs
8. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
9. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
10. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... VEGAS , March 27, 2015 Zimmer Holdings, Inc. (NYSE ... NexGen ® Complete Knee System. ... is the 20 th year since Zimmer first introduced the ... the market. To date, more than five million implantations of the ... year history of the NexGen knee demonstrates the importance of ...
(Date:3/27/2015)... , March 27, 2015 XRpro Sciences, ... drug discovery and development services which features high ... pharmaceutical industry, announced financial results for the year ... C.  Tyson, Chairman of XRpro Sciences commented, "We ... transition from development stage to commercial stage in ...
(Date:3/27/2015)... Report Details  New ... companies  What does the future hold for ... Visiongain,s brand new report shows you potential revenues to ... Our 242-page report provides 185 tables, charts, and ... and the future market prospects. Our new study lets ...
Breaking Medicine Technology:Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
... and EVANSTON, Ill., Oct. 20, The American College ... Simulation Research (CESR) of Western Michigan University,announced the ... in,situ simulation to improve the time from hospital ... angioplasty (D2B). Mentice Inc.,was selected as the exclusive ...
... Results Disclosed, SAN DIEGO, Oct. 20 ... "Best-in-Class" drugs for the,treatment of serious bacterial ... studies on its lead program, TR-701, and ... eighteen presentations at the upcoming joint,Interscience Conference ...
Cached Medicine Technology:American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time 2American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time 3American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time 4Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 2Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 3
(Date:3/27/2015)... (PRWEB) March 27, 2015 While deep learning ... 2015 GPU technology conference (GTC) , the CEO of one ... and push the human lifespan well beyond the generally-agreed ceiling ... informatics company , is one of 12 companies recognized as ... other startups in the GTC Emerging Companies Summit ...
(Date:3/27/2015)... UK (PRWEB) March 27, 2015 DrugDev ... Melissa (Liss) Easy was named to the 2015 Philadelphia ... Under 40 list spotlights 40 dynamic, up-and-coming leaders less ... and community involvement. Winners are honored at an awards ... of the Philadelphia Business Journal. , Lyn Kremer, Publisher ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The report ... an essential source of information on and analysis of ... The population of the US in 2013 amounted to ... Rate (CAGR) of 0.8% from 2008. The country’s increasingly ... chronic diseases will help to boost the growth of ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global ... the SM1120 MEMS based ultra-miniature pressure sensor designed especially ... at only 220um x 75um provides ample space for ... With industry leading in vivo drift performance of ... broad operating pressure range from 0 to 1,100 mmHg ...
(Date:3/27/2015)... When struck with the aftermath of a trucking ... begin. The latest eBook released by Dax Jones ... victims a clear and concise process for obtaining the ... injury claim is seen through to successful completion. , ... should be taken immediately following the trucking incident. From ...
Breaking Medicine News(10 mins):Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... new study shows that monitoring levels of exhaled nitric oxide ... improve the course of their disease. , The study ... is funded by the National Institute of Allergy and Infectious ... The Sept. 20 issue of The Lancet reports ...
... GetResearchSmart LLC serves as Guest Editor for a special issue of ... entitled Measuring Trust in Clinical Research. , ... St. ... of The Monitor, journal of the Association of Clinical Research Professionals ...
... ,do not board, list comes as a surprise to ... -- Thirty-three would-be air travelers with suspected or confirmed ... health "Do Not Board" list in the first year ... , Authorized under the Aviation and Transportation Security Act ...
... National Poll Shows Large Majority Supports Funding ... of the nation,s,largest veterans service organizations, representing ... Veterans, Affairs Committee Chairman Daniel,Akaka (D-Hawaii), House ... a group of bipartisan cosponsors for introducing,legislation ...
... a top concern for businesses of all sizes. Just when,employers ... these that complicate the enrollment:, -- Employees don,t ... of what their employer provides. -- Health ... -- A handful of employees who are located in remote ...
... WHITE PLAINS, N.Y., Sept. 18 Dee Snider,best known as ... Sister,is taking on a new lead role this year as ... is personal: two of his children were,born prematurely, and he,s ... Despite the wild-man image from his heavy metal days, Snider ...
Cached Medicine News:Health News:Monitoring exhaled nitric oxide does not help manage asthma 2Health News:Monitoring exhaled nitric oxide does not help manage asthma 3Health News:GetResearchSmart LLC Website Founder Honored as Guest Editor 2Health News:U.S. Barred 33 TB-Infected People From Flying Over Past Year 2Health News:U.S. Barred 33 TB-Infected People From Flying Over Past Year 3Health News:Historic Legislation to End Delays in Veterans Health Care Funding 2Health News:Historic Legislation to End Delays in Veterans Health Care Funding 3Health News:New Web-Based Enrollment System Gives Employers Flexibility and Control in Managing Benefits Enrollments 2Health News:New Web-Based Enrollment System Gives Employers Flexibility and Control in Managing Benefits Enrollments 3Health News:Dee Snider Joins March of Dimes Bikers for Babies(R) 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: